Overexpression of AGO2 was associated with high-risk myeloma and invasive hepatocellular carcinoma (HCC), while AGO2 knockdown caused a decline in viability and transferability of myeloma cell lines and HCC respectively [13, 15]. Here, AGO2 is linked to hepatocellular carcinoma.